AR Hosseinpour - Department of Cardiovascular Medicine, Shiraz University of MedicalSciences, Shiraz, Iran, TAHA Clinical Trial Group, Shiraz, Iran
A Attar - Department of Cardiovascular Medicine, Shiraz University of MedicalSciences, Shiraz, Iran, TAHA Clinical Trial Group, Shiraz, Iran

Objective: S tem cell therapy following revascularization in patientswith acute myocardial infarction (MI) has been proposedas a potential technique for better ventricular function and clinicaloutcomes. This s tudy aimed to explore the potential effectsof bone marrow mononuclear cell (BM-MNC) therapy on majoradverse cardiovascular events (MACE).Materials and Methods: We sys tematically search digitaldatabases for potential relevant randomized controlled trialsreporting the prevalence of adverse events including rehospitalizationfor heart failure, myocardial reinfarction, cardiacmortality, and the composite of endpoints following transplantationof BM-MNCs in patients with acute MI. We employedS tata software version ۱۳ for generating risk ratio (RR) usingthe random-effects model.Results: A total of ۲۳ trials were included after the initial screeningof ۱۵۴۰ records for meta-analysis. BM-MNC therapy ledto a significant lower risk of rehospitalization (RR=۰.۵۷, ۹۵%CI=۰.۳۸-۰.۸۴), reinfarction (RR=۰.۵۸, ۹۵% CI=۰.۳۴-۰.۹۹), andcomposite of endpoints (RR=۰.۶۴, ۹۵% CI=۰.۴۹-۸۴) in thefollow-up period. However, no change was observed in the occurrenceof cardiac-related mortality (RR=۰.۷۲, ۹۵%CI=۰.۴۴-۱.۲۰) compared to the control arm.Conclusion: Utilization of BM-MNCs in the setting of acuteMI can subs tantially cause a lower risk of rehospitalization forheart failure and recurrence of MI but it does not change the riskof cardiovascular mortality in the long term.

Bone Marrow Mononuclear Cell, Heart Failure, MyocardialInfarction, S tem Cell